Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 479
Gene Symbol: ATP12A
ATP12A
0.100 Biomarker disease BEFREE Vonoprazan versus proton-pump inhibitors for healing gastroesophageal reflux disease: A systematic review. 30883868 2019
Entrez Id: 479
Gene Symbol: ATP12A
ATP12A
0.100 GeneticVariation disease BEFREE Gastroesophageal reflux disease (GERD) can be treated using a vonoprazan-first strategy (first-line treatment with vonoprazan), or esomeprazole-first/rabeprazole-first strategies (first-line treatment with proton-pump inhibitors [PPIs], esomeprazole/rabeprazole, followed by a switch to vonoprazan). 31396703 2019
Entrez Id: 479
Gene Symbol: ATP12A
ATP12A
0.100 Biomarker disease BEFREE The aim of the current systematic review and network meta-analysis (NMA) was to assess the diagnostic characteristics of the gastroesophageal reflux disease questionnaire (GERDQ), proton-pump inhibitor (PPI) test, baseline impedance, mucosal impedance, dilated intercellular spaces (DIS), salivary pepsin, esophageal pH/pH impedance monitoring and endoscopy for gastroesophageal reflux disease (GERD). 31803253 2019
Entrez Id: 479
Gene Symbol: ATP12A
ATP12A
0.100 Biomarker disease BEFREE Systematic review with network meta-analysis: indirect comparison of the efficacy of vonoprazan and proton-pump inhibitors for maintenance treatment of gastroesophageal reflux disease. 30919071 2019
Entrez Id: 479
Gene Symbol: ATP12A
ATP12A
0.100 Biomarker disease BEFREE We aimed to assess the dynamic changes in the peripheral T lymphocytes and lymphocytes infiltrating the esophageal mucosa after treatment with proton-pump inhibitor (PPI) in patients with GERD. 30119091 2019
Entrez Id: 479
Gene Symbol: ATP12A
ATP12A
0.100 AlteredExpression disease BEFREE The main causes of refractory heartburn include: poor compliance; inadequate proton-pump inhibitors dosage; incorrect diagnosis; comorbidities; genotypic differences; residual gastroesophageal reflux; eosinophilic esophagitis and others. 29352757 2018
Entrez Id: 479
Gene Symbol: ATP12A
ATP12A
0.100 Biomarker disease BEFREE Secondary endpoints included cessation of proton-pump inhibitor (PPI), persistent dysphagia requiring intervention, and GERD health-related quality-of-life (HRQL) scores 1 year from surgery. 29340828 2018
Entrez Id: 479
Gene Symbol: ATP12A
ATP12A
0.100 Biomarker disease BEFREE The present study was aimed at evaluating, in dysphagic patients, the role of high-resolution manometry (HRM) findings, presence of gastroesophageal reflux disease (GERD), and proton-pump inhibitor (PPI) therapy on dysphagia perception. 28787356 2018
Entrez Id: 479
Gene Symbol: ATP12A
ATP12A
0.100 Biomarker disease BEFREE This is due to multiple factors, including overlaps in presentation with gastroesophageal reflux disease and proton-pump inhibitor responsive eosinophilia, remaining uncertainties regarding the role of different forms of allergy testing, and a variety of patient adherence issues. 30401322 2018
Entrez Id: 479
Gene Symbol: ATP12A
ATP12A
0.100 Biomarker disease BEFREE Higher economic status, smoking, and a history of proton-pump inhibitor use significantly increased the risk of GERD. 30427843 2018
Entrez Id: 479
Gene Symbol: ATP12A
ATP12A
0.100 Biomarker disease BEFREE Subgroup analysis was performed among studies that excluded gastroesophageal reflux disease or proton-pump inhibitor responsive esophageal eosinophilia, and also among pediatric and adult populations. 28787360 2018
Entrez Id: 479
Gene Symbol: ATP12A
ATP12A
0.100 Biomarker disease BEFREE GERD is a clinical diagnosis and is most effectively treated with proton-pump inhibitors (PPIs). 29132520 2017
Entrez Id: 479
Gene Symbol: ATP12A
ATP12A
0.100 Biomarker disease BEFREE Especially when proton-pump inhibitors failed to improve symptoms, other diagnosis should be considered, such as functional laryngeal disorders which are probably much more prevalent in these patients than pathologic gastroesophageal reflux. 28858946 2017
Entrez Id: 479
Gene Symbol: ATP12A
ATP12A
0.100 GeneticVariation disease BEFREE Retrospective analysis of LSG+sLHR patients >5 months postoperatively includes demographics, GERD status, proton-pump inhibitor (PPI) use, body mass index (BMI), excess BMI loss (EBMIL), complications and GERD-Health Related Quality of Life (GERD-HRQL) questionnaire. 27896401 2017
Entrez Id: 479
Gene Symbol: ATP12A
ATP12A
0.100 Biomarker disease BEFREE H2-receptor antagonists and proton-pump inhibitors provide more effective options for remission of GERD symptoms and healing of esophagitis. 28321555 2017
Entrez Id: 479
Gene Symbol: ATP12A
ATP12A
0.100 Biomarker disease BEFREE Food and Drug Administration approval of proton-pump inhibitors for infantile gastroesophageal reflux disease has been limited by intrapatient variability in the clinical assessment of gastroesophageal reflux disease. 27875488 2017
Entrez Id: 479
Gene Symbol: ATP12A
ATP12A
0.100 Biomarker disease BEFREE The reflux of pancreatic-duodenal fluids is implicated in the pathophysiology of proton-pump inhibitor-resistant gastroesophageal reflux disease (GERD). 26233549 2015
Entrez Id: 479
Gene Symbol: ATP12A
ATP12A
0.100 Biomarker disease BEFREE Associations were additionally tested for the confounding effect of covariates associated with a diagnosis of GERD and the use of proton-pump inhibitor medications (PPIs). 24894541 2014
Entrez Id: 479
Gene Symbol: ATP12A
ATP12A
0.100 Biomarker disease BEFREE The proton-pump inhibitor (PPI) test has been proposed as a valuable tool for diagnosing gastroesophageal reflux disease in Western populations. 19407662 2010
Entrez Id: 479
Gene Symbol: ATP12A
ATP12A
0.100 Biomarker disease BEFREE Maintenance therapy of gastroesophageal reflux disease (GERD) is usually performed with a low dose of a proton-pump inhibitor (PPI). 19259653 2009
Entrez Id: 479
Gene Symbol: ATP12A
ATP12A
0.100 Biomarker disease BEFREE Influence of cytochrome P450 2C19 genetic polymorphism and dosage of rabeprazole on accuracy of proton-pump inhibitor testing in Chinese patients with gastroesophageal reflux disease. 17559380 2007
Entrez Id: 479
Gene Symbol: ATP12A
ATP12A
0.100 Biomarker disease BEFREE This suggests that CYP2C19 genotype testing will not be useful in proton-pump inhibitor therapy of GERD, except perhaps in identifying patients at risk for hypochlorhydria and consequent hypergastrinemia. 12823155 2003